NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis has raised €10 million ($14.9 million) in a Series A financing round that included a handful of European investment firms.

The Lausanne, Switzerland-based firm is developing a multiplex, molecular diagnostics platform that will be able to quantify and amplify bio-analytes, such as proteins, nucleic acids, and small molecules. The firm said that it will use the proceeds from the private offering to develop a commercial version of its proprietary platform, as well as its first prototype assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.